Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2006, Pages

  Dennert, Gabriele ^a   Horneber, Markus ^b  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS DORTMUND   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SELENIUM; SODIUM SELENITE; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG INTOXICATION; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LYMPHEDEMA; PHYSIOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELENIUM DEFICIENCY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; NEOPLASM; POSTOPERATIVE COMPLICATION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; DIARRHEA; HUMANS; LYMPHEDEMA; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SODIUM SELENITE;

EID: 33750130890     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005037.pub2     Document Type: Review

References (85)

1. Kasseroller R. Prophylaxis of erysipelas in secondary lymphedemas with selenium [Erysipelprophylaxe beim sekundären Lymphodem mit Selen]. Der Allgemeinarzt 1996;18(3):244-7. 2922435
2. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Research 1998;18(3C):2227-30. 2922436
3. Micke 2003a: Micke O, Riesenbeck D, Büntzel J. Relevance of selenium supplementation in postoperative radiotherapy of head-neck-tumours and gynecologic pelvic tumours - A multi-center phase III study [Stellenwert der Selen-Substitution bei der postoperativen Strahlentherapie bei Kopf-Hals-Tumoren und gynäkologischen Beckentumoren - Eine multizentrische Phase-III-Studie]. www.uni-muenster.de'/rektorat/forschungsberichte-2001-2002/fo05aka15.htm (download 09.01.2004). 48149 Münster: Westfälische Wilhelms Universität, 2003. 5315577
4. Micke 2007: Micke O, Mücke R, Bruns F, Kisters K, Büntzel H. Some clinical results on selenium in radiation oncology. Letter by O Micke, R Mücke, F Bruns, K Kisters, J Büntzel on W. Dörr: Effects of selenium on radiation responses of tumor cells and tissue. Strahlentherapie und Onkologie 2007;183(6):344-5. 5315578
5. Mücke 2004a: Mücke R, Glatzel M, Bernd-Skorka R, Seifert G, Büntzel J, Schönekaes KG, et al. Adjuvant treatment with sodium selenite in gynecologic radiation oncology - first results of a phase III study. Abstract for the ESTRO meeting 2004 in Amsterdam. 2004. 5315569
6. Mücke 2004b: Mücke R, Glatzel M, Riesenbeck D, Bernd-Skorka R, Seifert G, Büntzel J, et al. Sodium selenite in gynecologic radiation oncology - first results of a phase III study. Trace Elements and Electrolytes 2004;21(2):78-82. 5315570
7. Mücke 2004c: Mücke R. Observation plan for the post-marketing surveillance stud: Use of selenase as complementary therapy to postoperative adjuvant radiotherapy of cervical and endometrial carcinoma. Version 1.4 [Beobachtungsplan der Anwendungsbeobachtung (AWB): Einsatz von selenase als Zusatztherapie zur postoperativen adjuvanten Radiotherapie bei Zervix- und Endometriumkarzinom. Version 1.4]. Biosyn Arzneimittel GmbH 2004. 5315571
8. Mücke 2004d: Mücke R. Use of selenase as supplementary therapy in postoperative adjuvant radiotherapy for cervical and endometrial carcinoma [Einsatz von selenase als Zusatztherapie zur postoperativen adjuvanten Radiotherapie bei Zervix- und Endometriumkarzinom]. http://www.studien.de/. 92637 Weiden, Söllnerstr.16: Dr. Ralph Mücke, Klinikum Weiden, download 16.01.2004. 5315572
9. Mücke 2006a: Mücke R, Glatzel M, Reichl B, Bernd-Skorka R, Baaske D, Kaiser A, et al. V 6 Sodium selenite in gynecologic radiation oncology - results of a prospective randomized observation study. AKTE. Münster: Diplodocus, 2006; Vol. Band 8. 5315573
10. Mücke 2006b: Mücke R, Glatzel M, Reichl B, Bernd-Skorka R, Büntzel J, Bruns F, et al. Sodium selenite in gynecologic radiation oncology: Results of a prospective randomized observation study. Trace Elements and Electrolytes 2006;23(3):173-7. 5315574
11. Mücke 2007a: Mücke R. Impact of Selenium in Radiation Oncology. Conference presentation at the 23rd Annual Meeting of the Society for Mineral and Trace Elements, 28.-29.09.2007 in Stuttgart/Germany 2007. 5315575
12. Mücke 2007b: Mücke R. The impact of sodium selenite in gynecologic radiation oncology - final results of a prospective randomized observation study. Submission abstract for conference presentation at the 23rd Annual Meeting of the Society for Mineral and Trace Elements 28.-29.09.2007 in Stuttgart/Germany 2007. 5315576
13. Leonhardt 2002: Leonhardt H. Impact of sodium selenite on the postoperative chronic lymphoedema and inflammatory cytokines in patients with stage T3 and T4 carcinomas of the base of the mouth and tongue [Wirkung von natrimselenit auf das postoperative chronische lymphödem und inflammatorische zytokine bei patienten mit mundboden- und zungengrundkarzinomen der stadien T3 und T4]. Thesis. Dresden: Technischen Universität Dresden, 2002. 5315579
14. Zimmermann T, Leonhardt H, Kersting S, Albrecht S, Range U, Eckelt U. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biological Trace Element Research 2005;106(3):193-203. 2922447
15. Asfour IA, El SS, Fayek MH, Hegab HM, Raouf S, Moussa MA. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients. Biological Trace Element Research 2006;110(1):19-32. 2922449
16. Badger C, Seers K, Preston N, Mortimer P. Antibiotics/anti-inflammatories for reducing acute inflammatory episodes in lymphoedema of the limbs. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003143.pub2]2922455
17. Büntzel J. Experiences with sodium selenite in treatment of acute and late adverse effects of radiochemotherapy of head-neck carcinomas. Cytoprotection working group in AK supportive measures in oncology within the scope of MASCC and DKG [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf-Hals-Karzinomen.]. Medizinische Klinik 1999;94(Suppl 3):49-53. 2922459
18. Elango N, Samuel S, Chinnakkannu P. Enzymatic and non-enzymatic antioxidant status in stage (III) human oral squamous cell carcinoma and treated with radical radio therapy: influence of selenium supplementation. Clinica Chimica Acta 2006;373(1-2):92-8. 2922463
19. Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, et al. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clinical Cancer Research 2006;12(4):1237-44. 2922465
20. Federico A, Iodice P, Federico P, Del Rio A, Mellone MC, Catalano G, et al. Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. European Journal of Clinical Nutrition 2001;55(4):293-7. 2922469
21. Fraunholz I, Jüling-Pohlit L, Böttcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors. Trace Elements and Electrolytes YR:2001. 18 Vol. 18:98-9. 2922473
22. Hoenjet KM, Dagnelie PC, Delaere KP, Wijckmans NE, Zambon JV, Oosterhof GO. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. European Urology 2005;47(4):433-9. 2922485
23. Hu Y, Lin Y, Xuemei S. Clinical study on the effect of kappa-selenocarrageenan in reducing the nephrotoxicity of cis-platin. Chinese New Drug Journal 1997;6:349-51. 5315580
24. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biological Trace Element Research 1997;56:331-41. 2922488
25. Kasseroller R. Sodium selenite in the therapy of chronic lymphedema [Natriumselenit in der Therapie des chronischen Lymphödems]. Der Allgemeinarzt 1995;17(13):1396-404. 2922494
26. Kiremidjian-Schumacher L, Roy M. Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions. BioFactors 2001;14(1-4):161-8. 2922497
27. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, et al. Selenium and immunocompetence in patients with head and neck cancer. Biological Trace Element Research 2000;73(2):97-111. 2922496
28. Kreienberg R. Prospective, randomised, 4-armed, controlled, open, multi-center phase-II-study: influence of selenium on the adverse effect profile of adjuvant chemotherapy in patients with mammacarcinoma [Prospektive, randomisierte, vierarmige, kontrollierte, offene, multizentrische Phase-II-Prüfung: Einfluss von Selen auf das Nebenwirkungsprofil von adjuvanter Chemotherapie bei Patientinnen mit Mammakarzinom]. online study register University of Ulm, Department for Gynecology: www.uni-ulm.de 2003. 2922499
29. Lasch K, Brasel C, Jahn H. Selenium therapy in colorectal tumors? [Selentherapie bei kolorektalen Tumoren?]. Medizinische Klinik 1999;94(Suppl 3):97-100. 2922504
30. Lasch K, Bräsel C, Jahn H. Selenium therapy for colorectal carcinoma [Poster: Selentherapie bei kolorektalen Karzinomen]. Poster. -- 2922503
31. Schumacher K. Influence of selenium on the adverse effect profile of adjuvant chemotherapy in patients with mammacarcinoma. Prospective, controlled, open, multi-center clinical study phase II [Einfluss von Selen auf das Nebenwirkungsprofil von adjuvanter Chemotherapie bei Patientinnen mit Mammakarzinom. Prospektive, kontrollierte, offene, multizentrische klinische Prüfung der Phase II]. www.studien.de (download 16.01.2004) 2002. 2922511
32. Schumacher K, Biosyn Arzneimittel GmbH. Study plan - Influence of selenium on the adverse effect profile of adjuvant chemotherapy in patients with mammacarcinoma. Prospective, randomised, 4-armed, controlled, open, multi-center clinical study phase II [Prüfplan - Einfluss von Selen auf das Nebenwirkungsprofil von adjuvanter Chemotherapie bei Patientinnen mit Mammakarzinom. Prospektive, randomisierte, vierarmige, kontrollierte, offene, multizentrische klinische Prüfung der Phase II]. biosyn Arzneimittel GmbH 2003. 2922510
33. Sieja K. Protective role of selenium against the toxicity of multi-drug chemotherapy in patients with ovarian cancer. Pharmazie 2000;55(12):958-9. 2922513
34. Sundström H, Korpela H, Viinikka L, Kauppila A. Serum selenium and glutathione peroxidase, and plasma lipid peroxides in uterine, ovarian or vulvar cancer, and their responses to antioxidants in patients with ovarian cancer. Cancer Letters 1984;24(1):1-10. 2922515
35. Sundström H, Korpela H, Sajanti E, Kauppila A. Supplementation with selenium, vitamin E and their combination in gynaecological cancer during cytotoxic chemotherapy. Carcinogenesis 1989;10(2):273-8. 2922517
36. Wagler E, Schwokowski C, Schönfelder M. Poster: first results of selenium supplementation in patients with gastrointestinal tumours [Poster: Erste Ergebnisse der Selensubstitution bei Patienten mit gastrointestinalen Tumoren]. Poster. Universitätsklinikum Leipzig, 2000. 2922521
37. Xu H, Mei W, Dong Z, Liao B. Study of the oxidative metabolic function and chemotaxis of neutrophils from patients with cancer influenced by selenium yeast. Biological Trace Element Research 1990;25(3):201-9. 2922523
38. Xu B, Sun Y. Randomized double-blind placebo-controlled phase II clinical trial of kappa-selenocarrageenan in cancer chemotherapy patients. Chinese Journal of Clinical Oncology 1999;26(9):678-80. 2922525
39. Yu B, Wang M, Li D. [The relationship between selenium and immunity in large bowel cancer]. Zhonghua Wai Ke Za Zhi 1996;34(1):50-3. 2922527
40. Büntzel 2002: Büntzel J. Use of selenase as complementary treatment to radiotherapy for tumours of the head and neck region [Einsatz von selenase als Zusatztherapie zur Radiotherapie bei Tumoren im Hals-Nasen-Ohrenbereich]. www.studien.de (retrieved on 16.01.2004) 2002. 5315582
41. Büntzel J, Biosyn Arzneimittel GmbH. Observation plan of a post-marketing surveillance study. Use of selenase as complementary treatment to radiotherapy of tumours of the head and neck region (version 1.4) [Beobachtungsplan der Anwendungsbeobachtung (AWB). Einsatz von selenase als Zusatztherapie zur Radiotherapie bei Tumoren im Hals-Nasen-Ohrenbereich (version 1.4.)]. biosyn Arzneimittel GmbH 2004. 5315583
42. Micke 2003b: Micke O, Riesenbeck D, Büntzel J. Importance of selenium supplementation in postoperative radiotherapy of head-neck-tumours and gynecological tumours of the pelvis - A multi-centre phase III study [Stellenwert der Selen-Substitution bei der postoperativen Strahlentherapie bei Kopf-Hals-Tumoren und gynäkologischen Beckentumoren - Eine multizentrische Phase-III-Studie]. www.uni-muenster.de'/rektorat/forschungsberichte-2001-2002/fo05aka15.htm (download 09.01.2004). Münster: Westfälische Wilhelms Universität, 2003. 5315584
43. Arnold-von Versen B. Use of micronutrients for tumour diseases and tumour prevention [Der einsatz von mikronährstoffen bei tumorerkrankungen und zur tumorprävention]. Deutsche Zeitschrift für Onkologie 2001;33:19-29.
44. Baehr K, Dreher I, Koehrle J. Selenium supplementation by selenium yeast and sodium selenite: Analysis of the selenium status as well as risks of deficiency and intoxication [Selensupplementation durch selenhefe und natriumselenit: analyse des selenstatus sowie risiken des mangels und der intoxikation]. The Journal of Laboratory and Clinical Medicine 1999;23(11):594-9.
45. Baldew GS, van den Hamer CJ, Los G, Vermeulen NP, De Goeij JJ, McVie JG. Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats. Cancer Research 1989;49(11):3020-3.
46. Beuth J, Uhlenbruck G. Evidence-based complementary therapy measures for prostate carcinoma [Evidenzbasierte komplementäre therapiemaßnahmen beim prostatakarzinom]. Deutsche Zeitschrift für Onkologie 2002;34:86-90.
47. Beuth J, Schierholz JM. Evidence-based complementary oncology. Innovative approaches to optimize standard therapy strategies. In Vivo 2007;21(2):423-8.
48. Boucher F, Coudray C, Tirard V, Barandier C, Tresallet N, Favier A, de Leiris J. Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 1995;11(5 Suppl):708-11.
49. Bruns F, Micke O, Bremer M. Current status of selenium and other treatments for secondary lymphedema. The Journal of Supportive Oncology 2003;1(2):121-30.
50. Cheetham PJ, Le Monnier KJ, Brewster SF. Attitudes and use of alternative therapies in UK prostate cancer patients - isńt it time we we were in the know?. Prostate Cancer and Prostatic Diseases 2001;4:235-41.
51. DCTD, NCI, NIH, DHHS . Cancer therapy evaluation program: Common terminology criteria for adverse effects. http://ctep.cancer.gov/reporting/ctcnew.html 2004.
52. Dennert G, Zwahlen M, Brinkmann M, Vinceti M, Zeegers MPA, Horneber MA. Selenium for preventing cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005195]
53. Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H. The chronic larynx oedema as delayed reaction after radiochemotherapy [Das chronische larynxödem als spätreaktion nach radiochemotherapie]. HNO 1998;46:731-8.
54. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. Journal of the National Cancer Institute 2001;93(2):96-111.
55. Francescato HD, Costa RS, Rodrigues Camargo SM, Zanetti MA, Lavrador MA, et al. Effect of oral selenium administration on cisplatin-induced nephrotoxicity in rats. Pharmacological Research 2001;43(1):77-82.
56. Greim H. Selenium and its anorganic compounds [Selen und seine anorganischen Verbindungen]. Gesundheitsschädliche Arbeitsstoffe. Toxikologisch-arbeitsmedizinische Begruendungen von MAK-Werten. Vol. Looseleaf: Supplement, Weinheim: Wiley-VCH, 1999.
57. Greim H. Selenium and its inorganic compounds [Selen und sein anorganischen Verbindungen]. In: Greim H editor(s). Gesundheitsschaedliche Arbeitsstoffe. Toxikologisch-arbeitsmedizinische Begruendungen von MAK-Werten. Vol. Looseleaf: Supplement, Weinheim: Wiley-VCH, 1999-2003.
58. Groetz KA, Riesenbeck D, Doerr W. The oral cavity of patients with head-neck-radiotherapy - III. Postradiotherapeutic care [Die mundhöhle des patienten mit kopf-hals-strahlentherapie - III. Postradiotherapeutische betreuung]. Im Focus Onkologie 2003;7-8:58-61.
59. Hatfield DL (Ed). Selenium. Its molecular biology and role in human health. Boston/Dordrecht/London: Kluwer Academic Publishers, 2001.
60. Helzlsouer K, Jacobs R, Morris S. Acute selenium intoxication in the United States. Federation Proceedings 1985;44:1670-2.
61. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
62. Jensen R, Claoson W. Selenium intoxication. New York Morbidity and Mortality Weekly Report 1984;33:157-60.
63. Juni P, Altman DG, Egger M. Assessing the methodological quality of randomised controlled trials. In: Egger M, Smith GD, Altman DG editor(s). Systematic Reviews in Health Care. 2nd Edition. London: BMJ Publishing Group, 2001:87-109.
64. Kasseroller RG, Schrauzer GN. Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: a review. American Journal of Therapeutics 2000;7(4):273-9.
65. Kotamraju S, Konorev EA, Joseph J, et al. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. Journal of Biological Chemistry 2000;275:33585-92.
66. Micke O, Bruns F, Mucke R, Schafer U, Glatzel M, DeVries AF, et al. Selenium in the treatment of radiation-associated secondary lymphedema. International Journal of Radiation Oncology Biology Physics 2003;56(1):40-9.
67. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
68. Nam RK, Fleshner N, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiologic analysis. Journal of Urology 1999;161:1521-4.
69. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. British Journal of Cancer 1988;58(1):38-41.
70. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology 1982;5:649-55.
71. Petru E, Schmied P, Petru C. Complementary measures with gynecological cancer patients during chemo- and radiotherapy - review and critical consideration of practical issues [Komplementäre maßnahmen bei patientinnen mit gynäkologischen malignomen unter chemo-und strahlentherapie - bestandsaufnahme und kritische uberlegungen für die praxis]. Geburtshilfe Frauenheilkunde 2001;61:75-8.
72. Pfeffer H. Severe incident with selenium medication [Schwerwiegender zwischenfall bei selen-medikation]. Hamburger Zahnärzteblatt 2002;42(3):3.
73. Rodemann HP, Hehr T, Bamberg M. Relevance of the radioprotective effect of sodium selenite [Relevanz der radioprotektiven Wirkung von Natriumselenit]. Medizinische Klinik 1999;94(Suppl III):39-41.
74. Sagowski C, Wenzel S, Tesche S, Jenicke L, Kehrl W, Roeser K, Metternich FU. Sodium selenite reduces acute radiogenic damage of the rat parotid glands during fractionated irradiation [Reduktion akuter radiogener schädigungen durch natriumselenit. Wirksamkeit unter fraktionierter bestrahlung der glandula parotis der ratte]. HNO 2004;52(12):1067-75.
75. Schleicher UM, Lopez Cotarelo C, Andreopoulos D, Handt S, Ammon J. Radioprotection of human endothelial cells by sodium selenite [Radioprotektion humaner endothelzellen durch natriumselenit]. Medizinische Klinik 1999;94(Supp. III):35-8.
76. See KA, Lavercombe PS, Dillon J, Ginsberg R. Accidental death from acute selenium poisoning. The Medical Journal of Australia 2006;185(7):388-9.
77. Sehouli J, David M, Kaufmann B, Lichtenegger W. Unconventional methods in cancer medicine - postoperative use by patients with gynecologic malignomas [Unkonventionelle methoden in der krebsmedizin - postoperative nutzung durch patientinnen mit gynäkologischen malignomen]. Geburtshilfe Frauenheilkunde 2000;60:146-54.
78. Sill-Steffens R. Selenium in oncology [Selen in der onkologie]. Deutsche Zeitschrift fur Onkologie 2003;35:112-22.
79. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiotherapy & Oncology 2003;66(3):253-62.
80. Verhagen AP, De Vet HC, De Bie RA, Kessels AGH, Boers M, Boeter LM, et al. The Delphi List: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by delphi consensus. Journal of Clinical Epidemiology 1998;51(12):1235-41.
81. Vinceti M, Wei ET, Malagoli C, Bergomi M, Vivoli G. Adverse health effects of selenium in humans. Reviews in Environmental Health 2001;16(4):233-51.
82. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treatment Reviews 1997;23(4):209-40.
83. Yoshida M, Iizuka K, Terada A, et al. Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. The Tohoku Journal of Experimental Medicine 2000;191:209-20.
84. Zimmermann T, Albrecht S, Kuhne H, Vogelsang U, Grutzmann R, Kopprasch S. Selenium administration in patients with sepsis syndrome. A prospective randomized study [Selensubstitution bei Sepsispatienten]. Medizinische Klinik 1997;92 Suppl 3:3-4.
85. Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005037.pub2]